Skip to main
CDNA
CDNA logo

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

CareDx Inc has demonstrated strong financial performance, with a reported revenue growth of 19% year-over-year in 2024 and an anticipated 17% growth for 2025, attributing this success primarily to its testing services. The company achieved total revenue of $86.6 million in 4Q24, reflecting a 32% year-over-year increase, which surpassed projections and indicates a robust demand for its products and services. CareDx's growth strategy focuses on expanding testing volumes through a comprehensive go-to-market strategy, increased payer coverage, and operational efficiencies, positioning the company to reach its long-term revenue target of $500 million by 2027.

Bears say

CareDx Inc faces significant risks that contribute to a negative outlook for its stock, primarily stemming from potential reimbursement challenges, which could severely impact financial results if the company fails to secure adequate reimbursement for its testing services. The competitive landscape poses another threat, as the emergence of superior testing solutions from rivals could lead to a loss of market share, further jeopardizing CareDx's financial stability. Additionally, external factors such as healthcare policy changes and stringent regulations in the diagnostics industry, as well as integration risks associated with acquisitions, could adversely affect the company's financial performance and growth prospects.

CareDx (CDNA) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 11 analysts, CareDx (CDNA) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.